News-Medical.Net on MSN
Recent advances in CAR-NK cell therapy could revolutionze cancer treatment
Cell-based immunotherapies have transformed cancer treatment, yet their widespread use remains constrained by safety risks, ...
A new method for engineering natural killer cells could make cancer immunotherapy more efficient, scalable, and affordable, ...
Friday, ImmunityBio said the two complete responses are ongoing after seven and 15 months. The patients received four cycles ...
CAR T cells have made headlines for their ability to fight hematological cancers, but they have proven largely ineffective ...
News Nation on MSN
Patrick Soon-Shiong’s cancer drug approved by Saudi FDA
Dr. Soon-Shiong is hopeful the Saudi Arabian FDA's approval of his cancer therapy drug, Anktiva, will lead to widespread ...
GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE(R) natural killer (NK ...
Techno-Science.net on MSN
A method to produce anti-cancer killer cells en masse
Natural killer cells, or NK cells, are elements of the immune system capable of rapidly locating and destroying cancerous or ...
Morning Overview on MSN
New method could mass-produce cancer-fighting natural killer cells
Cancer immunotherapy has been transformed by engineered T cells, but those bespoke treatments are slow, expensive, and out of ...
Chimeric antigen receptor natural killer (CAR-NK) cell therapy is emerging as a promising next-generation immunotherapy with ...
A group of researchers in Japan says it has confirmed a certain level of efficacy in using iPS cell-derived immune cells for ...
GT Biopharma submitted an IND application for GTB-5550 TriKE for solid tumors. Phase 1 trial planned for 2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback